The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The Influence of Finasteride on the Development of Prostate Cancer
Open accessAbstract
BACKGROUND: Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. METHODS: In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study. RESULTS: Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo. CONCLUSIONS: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationCANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS
HULL, G. W., RABBANI, F., ABBAS, F., WHEELER, T. M., KATTAN, M. W., & SCARDINO, P. T. (2002) · Journal of Urology · doi:10.1016/s0022-5347(01)69079-7 · Cited by 964
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., & Kantoff, P. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3320 · Cited by 873
Albertsen, P. C. (1998) · JAMA · doi:10.1001/jama.280.11.975 · Cited by 717
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
Ross, R. K., Bernstein, L., Pike, M. C., Henderson, B. E., Lobo, R. A., Stanczyk, F. Z., & Shimizu, H. (1992) · The Lancet · doi:10.1016/0140-6736(92)90927-u · Cited by 495
Hormones and prostate cancer: Current perspectives and future directions
Hsing, A. W., Reichardt, J. K. V., & Stanczyk, F. Z. (2002) · The Prostate · doi:10.1002/pros.10108 · Cited by 208
Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D., Hudson, P., Jackson, C. L., Romas, N. A., Patterson, L., et al. (1998) · Urology · doi:10.1016/s0090-4295(98)00184-8 · Cited by 202
Krumholtz, J. S., Carvalhal, G. F., Ramos, C. G., Smith, D. S., Thorson, P., Yan, Y., Humphrey, P. A., Roehl, K. A., & Catalona, W. J. (2002) · Urology · doi:10.1016/s0090-4295(02)01875-7 · Cited by 170
Design of the Prostate Cancer Prevention Trial (PCPT)
Feigl, P., Blumenstein, B. A., Thompson, I. M., Crowley, J. J., Wolf, M., Kramer, B. S., Coltman, C. A., Brawley, O. W., & Ford, L. G. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00xxx-m · Cited by 132
Self-citationYang, X. J., Lecksell, K., Short, K., Gottesman, J. E., Peterson, L. J., Bannow, J., Schellhammer, P. F., Fitch, W. P., Hodge, G. B., Parra, R. O., et al. (1999) · Urology · doi:10.1016/s0090-4295(98)00579-2 · Cited by 102
Smith, D. M., & Murphy, W. M. (1994) · Cancer · doi:10.1002/1097-0142(19940301)73:5<1472::aid-cncr2820730525>3.0.co;2-m · Cited by 90
Schatzl, G., Stephan Madersbacher, A., Haitel, A., Gsur, A., Preyer, M., Haidinger, G., Gassner, C., OCHSNER, M., & Marberger, M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000056900.26628.16 · Cited by 88
Biomarker-based methods for determining noncompliance in a prevention trial
Ankerst, D. P., Gower, K. B., Goodman, P. J., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00231-3 · Cited by 11
Self-citation
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationLippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., et al. (2009) · JAMA · doi:10.1001/jama.2008.864 · Cited by 2,122
Self-citationMcConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Self-citation
Metadata
- Authors
- Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., & Coltman, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-17
- Volume
- 349
- Issue
- 3
- Pages
- 215-224
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133929387
- Cited by
- 2,518
- References
- 17
- FWCI
- 128.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.